Policy and Advocacy Program
NCCN works with policymakers, regulatory agencies, and payers to ensure appropriate use of NCCN Guidelines in legislation, regulation, coverage policy, and cancer quality and value programs.
NCCN works with policymakers, regulatory agencies, and payers to ensure appropriate use of NCCN Guidelines in legislation, regulation, coverage policy, and cancer quality and value programs.
The NCI SBIR Innovation Lab podcast reaches and engages with entrepreneurs of all levels to share insights on commercialization and success stories from biotech industry…
A.gov website belongs to an o fficial government organization in the United States. A lock () or https:// means you’ve safely connected to the .gov…
Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.
A Roswell Park-led team uncovers beneficial effects of combining VEGFR-targeting TKIs with checkpoint inhibitors in new research.
Pembrolizumab plus chemotherapy did not improve disease-free survival in patients with newly diagnosed, high-risk endometrial cancer, missing the primary end point of the phase 3…
The Biden administration has—for the second time—delayed the decision on a proposed FDA rule that would ban menthol cigarettes and all flavors in cigars. To…
Blood | 143 | 19 | May 2024
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Cancer research is a vast, complex enterprise that involves researchers from many different disciplines, working across a research continuum, to produce biomedical advances. Each advance…